Axa
KURA icon

Axa’s Kura Oncology KURA Stock Holding History

Axa’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-296,184
Closed -$3.68M – 1143
2022
Q4 		$3.68M Sell
296,184
-1,603
-0.5% -$23.3K 0.01% 668
2022
Q3 		$4.07M Sell
297,787
-66,762
-18% -$1.03M 0.02% 622
2022
Q2 		$6.68M Sell
364,549
-7,091
-2% -$102K 0.02% 513
2022
Q1 		$5.98M Buy
371,640
+55,788
+18% +$806K 0.02% 600
2021
Q4 		$4.42M Buy
315,852
+145,626
+86% +$2.36M 0.01% 689
2021
Q3 		$3.19M Buy
170,226
+6,269
+4% +$118K 0.01% 774
2021
Q2 		$3.42M Sell
163,957
-12,454
-7% -$309K 0.01% 791
2021
Q1 		$4.99M Buy
176,411
+3,270
+2% +$103K 0.02% 713
2020
Q4 		$5.66M Sell
173,141
-44,022
-20% -$1.55M 0.02% 664
2020
Q3 		$6.65M Sell
217,163
-97,708
-31% -$2.16M 0.02% 556
2020
Q2 		$5.13M Sell
314,871
-11,184
-3% -$161K 0.02% 605
2020
Q1 		$3.24M Buy
+326,055
New +$3.73M 0.02% 632

Other funds holding KURA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Axa's KURA Position: Q1 2023 in Review

Axa sold out of Kura Oncology (KURA) in Q1 2023, closing a stake of 296,184 shares — an estimated $3.68M sold.

Axa first reported a position in KURA in Q1 2020 and held it in 12 quarters. The position peaked at $6.68M in Q2 2022. 141 funds tracked by Wall St. Rank hold KURA as of Q1 2023.

  • Axa reported no remaining Kura Oncology position as of Q1 2023 after selling out during the quarter.
  • Axa sold 296,184 Kura Oncology shares in Q1 2023, an estimated $3.68M.
  • Axa first reported a position in Kura Oncology in Q1 2020 and held it in 12 quarters.
  • Axa's Kura Oncology position peaked at $6.68M in Q2 2022.
  • 141 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2023.

Based on Axa's 13F filing for Q1 2023, filed 15 May 2023.